8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Feb 24, 2026·SEC
Vaxcyte, Inc.(PCVX)Earnings, Financials & Key Ratios
PCVX•NASDAQ
$60.67
Price updated Jul 7, 2026
AboutVaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Show more
- Revenue$0
- EBITDA-$899M-62.3%
- Net Income-$767M-65.2%
- EPS (Diluted)-5.63-48.2%
- ROE-25.59%-25.4%
PCVX Price & Volume
Vaxcyte, Inc. (PCVX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Revenue Generation Potential
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
Key Thesis Takeaways
- Vaxcyte remains a pre-revenue, clinical-stage entity heavily reliant on external capital to fund its $312.8 million quarterly R&D expenditure as of 2026Q1.
- While the company has successfully fortified its balance sheet to $3.3 billion in total assets, the persistent negative free cash flow and reliance on equity-based incentives create significant dilution risks for long-term shareholders.
- Investors should monitor the company's ability to navigate competitive immunological hurdles and potential milestone obligations to Sutro Biopharma, which may materially impact future profitability.
Verdict Logic
while the company maintains a robust current ratio of 7.49, the lack of revenue and a $295.4 million quarterly free cash flow burn necessitate extreme caution regarding future capital dilution.
PCVX Growth Metrics
Vaxcyte, Inc. (PCVX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-85.73%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-68.46%
Return on Capital
10 Years-47.03%
5 Years-33.1%
3 Years-32.11%
Last Year-29.74%
PCVX Recent Earnings
Vaxcyte, Inc. (PCVX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$2.30-29.4%
$1.78
Rev
—
$13M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$1.80-17.7%
$1.53
Rev
—
$19M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$1.56-22.8%
$1.27
Rev
—
—
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$1.22-8.9%
$1.12
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $2.30vs $1.78-29.4% | —vs $13M |
| Q1 2026 | Feb 24, 2026 | $1.80vs $1.53-17.7% | —vs $19M |
| Q4 2025 | Nov 4, 2025 | $1.56vs $1.27-22.8% | — |
| Q3 2025 | Aug 6, 2025 | $1.22vs $1.12-8.9% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Vaxcyte, Inc. (PCVX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $60.67 | $8.76B | -10.78 | — | — | -25.59% | — | |
| $24.07 | $136.92B | 17.70 | -1.65% | 11.83% | 8.34% | — | |
| $128.86 | $318.26B | 17.70 | 1.18% | 13.62% | 17.91% | — | |
| $53.32 | $107.23B | 7.16 | 4.11% | 19.19% | 31.48% | — | |
| $42.98 | $103.34B | 11.75 | 5.49% | 16.72% | 10.78% | — | |
| $94.29 | $23.84B | -18.30 | 0.2% | -44.95% | -6.72% | — |
Compare PCVX vs Peers
Vaxcyte, Inc. (PCVX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PCVX SEC Filings & Documents
Vaxcyte, Inc. (PCVX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PCVX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PCVX Frequently Asked Questions
Vaxcyte, Inc. (PCVX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is PCVX profitable?
Vaxcyte, Inc. (PCVX) reported a net loss of $946.5M for fiscal year 2025.
Dividend & Returns
What is PCVX's return on equity?
Vaxcyte, Inc. (PCVX) has a return on equity (ROE) of -25.6%. Negative ROE indicates the company is unprofitable.
What is Vaxcyte, Inc.'s free cash flow?
Vaxcyte, Inc. (PCVX) had negative free cash flow of $771.7M in fiscal year 2025, likely due to heavy capital investments.